key: cord-0903712-hr2dasnp
authors: Zang, Ruochen; Case, James Brett; Yutuc, Eylan; Ma, Xiucui; Shen, Sheng; Gomez Castro, Maria Florencia; Liu, Zhuoming; Zeng, Qiru; Zhao, Haiyan; Son, Juhee; Rothlauf, Paul W.; Kreutzberger, Alex J. B.; Hou, Gaopeng; Zhang, Hu; Bose, Sayantan; Wang, Xin; Vahey, Michael D.; Mani, Kartik; Griffiths, William J.; Kirchhausen, Tom; Fremont, Daved H.; Guo, Haitao; Diwan, Abhinav; Wang, Yuqin; Diamond, Michael S.; Whelan, Sean P. J.; Ding, Siyuan
title: Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
date: 2020-12-15
journal: Proc Natl Acad Sci U S A
DOI: 10.1073/pnas.2012197117
sha: b5facbe05d776c818e5b45b2ad035c58a509b2db
doc_id: 903712
cord_uid: hr2dasnp

Cholesterol 25-hydroxylase (CH25H) is an interferon (IFN)-stimulated gene that shows broad antiviral activities against a wide range of enveloped viruses. Here, using an IFN-stimulated gene screen against vesicular stomatitis virus (VSV)-SARS-CoV and VSV-SARS-CoV-2 chimeric viruses, we identified CH25H and its enzymatic product 25-hydroxycholesterol (25HC) as potent inhibitors of SARS-CoV-2 replication. Internalized 25HC accumulates in the late endosomes and potentially restricts SARS-CoV-2 spike protein catalyzed membrane fusion via blockade of cholesterol export. Our results highlight one of the possible antiviral mechanisms of 25HC and provide the molecular basis for its therapeutic development.

T he novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID-19) (1, 2), has infected millions of people worldwide and caused hundreds of thousands of deaths. Currently, there are no Food and Drug Administration-approved vaccines available. In most instances, treatment is limited to supportive therapies to help alleviate symptoms. With the concern that monotherapy would rapidly result in the emergence of resistance, there is a pressing need to identify multiple effective antivirals as countermeasures before safe and efficacious vaccines are developed and deployed. Here, we sought to harness the host innate immune responses to inhibit SARS-CoV-2 replication. Interferons (IFNs) are a group of small, secreted proteins (3, 4) that potently suppress the replication of many viruses through the action of hundreds of IFNstimulated genes (ISGs) (5) . IFN and ISG levels are up-regulated in SARS-CoV-2-infected cells and lung tissues from COVID-19 patients (6, 7) . Compared to SARS-CoV, SARS-CoV-2 appears to be more sensitive to the antiviral activities of IFNs (8) . SARS-CoV-2 replication is inhibited by IFN treatment in both immortalized and primary cells (9) (10) (11) . While direct IFN administration often results in adverse effects in humans (12, 13) , a targeted approach of activating the antiviral effects of specific ISGs holds promise.

To identify potential ISG effector proteins that act to block coronavirus (CoV) at the entry or egress stages of the replication cycle, we utilized replication-competent chimeric vesicular stomatitis virus (VSV) eGFP reporter viruses decorated with either fulllength SARS-CoV spike (S) protein or SARS-CoV-2 S in place of the native glycoprotein (G) (14) . We used an HEK293 cell line that stably expresses plasma membrane-localized mCherry-tagged human ACE2, the SARS-CoV and SARS-CoV-2 receptor (2, 15-17) (SI Appendix, Fig. S1A ). HEK293-hACE2-mCherry cells supported 100-fold more VSV-SARS-CoV-2 replication than wildtype HEK293 cells (SI Appendix, Fig. S1 B-D). We recently showed robust SARS-CoV-2 infection of primary human intestinal enteroids (18) . By RNA-sequencing of these intestinal enteroid cultures, we identified the ISGs most highly and commonly induced by type I IFN (IFN-β) and type III IFN (IFN-λ). We transduced HEK293-hACE2 stable cells with lentiviruses encoding 57 of these individual ISGs and tested their ability to suppress VSV-SARS-CoV and VSV-SARS-CoV-2 replication.

The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the etiological agent of coronavirus disease-2019 (COVID- 19) , has swept the world in unprecedented speed. In a few months, SARS-CoV-2 has infected millions of people and caused tens of thousands of deaths. There are no Food and Drug Administration-approved antivirals or vaccines yet available and clinical treatments are limited to supportive therapies that help alleviate the symptoms. Thus, there is an urgent need to identify effective antivirals as countermeasures before safe and effective vaccines are developed, tested, and then produced on a large scale. Our approach is to harness the germline-encoded interferon antiviral response to inhibit SARS-CoV-2 replication thereby limiting its pathogenicity.

Ectopic expression of AXIN2, CH25H, EPSTI1, GBP5, IFIH1, IFN-induced transmembrane protein (IFITM)-2, IFITM3, and LY6E resulted in a marked reduction (<36%) in the infectivity of both viruses, indicated by the number of GFP-infected cells ( Fig. 1A and Dataset S1). Among these genes, IFIH1 (which encodes MDA5) activates IFN signaling upon ectopic expression (19) . LY6E and IFITMs recently were reported to inhibit SARS-CoV-2 (20) (21) (22) and thus served as positive controls for our assay. We validated the top candidates in HEK293-hACE2 cells expressing CH25H, IFITM1, IFITM2, or IFITM3 (SI Appendix, Fig. S1E) . Consistent with our screen results, the expression of IFITM2 or IFITM3 but not IFITM1 suppressed VSV-SAR-S-CoV-2 infection, as evident by a reduction in viral mRNA and protein levels ( Fig. 1B and SI Appendix, Fig. S1F ). CH25H was comparable to IFITM2 and blocked virus replication at 18 h postinfection (hpi) (Fig. 1B) .

CH25H encodes cholesterol 25-hydroxylase that catalyzes the formation of 25-hydroxycholesterol (25HC) from cholesterol (23) . In many cell types, 25HC is further converted to 7-α, 25-dihydroxycholesterol , an oxysterol that functions as a chemoattractant for T cells and B cells (24) . 25HC exhibits broad inhibitory activities against enveloped viruses of different families (25, 26) , including two porcine CoVs (27) . Within a singlecycle of replication (6 hpi), CH25H expression slightly inhibited the replication of VSV-SARS-CoV and VSV-SARS-CoV-2 viruses, as detected by measurement of eGFP expression using flow cytometry (Fig. 1C ). CH25H also decreased wild-type VSV replication (Fig. 1C ), as previously reported (28) . We interpret the partial reduction of eGFP fluorescence intensity in the infected cells as an indication that CH25H treatment slows down the kinetics of infection. In contrast, rotavirus and adenovirus replication were not affected (Fig. 1D ). Un-like IFIH1, CH25H expression or 25HC treatment did not induce type I or type III IFN expression (SI Appendix, Fig. S1G ). The replication of a clinical isolate of SARS-CoV-2 (2019-nCoV/USA-WA1/2020 strain) also was suppressed in HEK293-hACE2 cells expressing CH25H compared to control plasmid transfection (Fig. 1E) .

To examine the physiological relevance of CH25H antiviral activity, we used CRISPR/Cas9 to edit the endogenous CH25H locus. CH25H knockout was verified by both Sanger sequencing and Western blot (SI Appendix, Fig. S1 H and I). Genetic depletion of CH25H expression resulted in a significant increase of VSV-SARS-CoV-2 replication (Fig. 1F ). Taking these data together, our genetic screen revealed CH25H as a host restriction factor of SARS-CoV-2 replication.

Next, we tested whether the antiviral activity of CH25H depends on 25HC synthesis. As compared to the control 7-α, 25-diHC, pretreatment of HEK293-hACE2 cells with 25HC for 1 h prior to VSV-SARS-CoV-2 infection recapitulated the suppressive effect of CH25H overexpression and reduced virus replication ( Fig. 2A) . 25HC dose-dependently inhibited VSV-SARS-CoV-2 infection in MA104 cells, with an approximate EC 50 of 1.49 μM (with 95% confidence interval of 1.09 to 2.08 μM) (Fig. 2B) . The 50% cytotoxic concentration (CC 50 ) was calculated to be at 239 μM. Thus, 25HC had an excellent selectivity index of 160. When plaque assays were performed in the presence of 25HC, there was a reduction in both plaque numbers and sizes (SI Appendix, Fig. S2 A and B) . Similarly, wild-type SARS-CoV-2 virus replication was inhibited by 25HC treatment (Fig. 2C) . The infectivity of a lentivirus backbone-based SARS-CoV-2 pseudovirus also was suppressed by 25HC, suggesting that the antiviral effect is restricted to early-stage virus replication (entry, transcription, translation, and so forth). We and others previously showed that primary human intestinal epithelial cells and cardiomyocytes are extrapulmonary SARS-CoV-2 target cells (7, 18, 29) . Importantly, 25HC inhibited VSV-SARS-CoV-2 replication in these primary cell culture systems in a dose-dependent manner ( Fig. 2 E and F and SI Appendix, Fig. S2C ).

To investigate a potential 25HC-independent antiviral function of CH25H (30), we generated a CH25H catalytic mutant (H422Q and H423Q). Using liquid chromatography-mass spectrometry (LC-MS), we quantified the secreted and intracellular levels of 25HC and downstream product 7-α, 25-diHC. At similar protein levels (SI Appendix, Fig. S2D ), mutant CH25H did not produce 25HC and 7-α, 25-diHC ( Fig. 2G and SI Appendix, Fig.  S2E ). As expected, mutant CH25H failed to inhibit VSV-SAR-S-CoV-2 infection like the wild-type protein (Fig. 2H ). Collectively, our results suggest the natural product 25HC mediates the antiviral activity of CH25H and restricts SARS-CoV-2 virus infection.

During SARS-CoV-2 entry into host cells, S protein binding to ACE2 enables its cleavage by membrane-bound TMPRSS serine proteases and subsequent fusion of the viral membrane to the host cell membrane (15, 18, 31) . Previous work suggests that trypsin treatment or TMPRSS2 expression alleviates IFITM-mediated restriction of SARS-CoV and HCoV-229E entry (32, 33) . Furthermore, TMPRSS2 is abundantly expressed in human nasal and intestinal epithelial cells (18, 34) . Thus, we examined whether the presence of TMPRSS2 assists VSV-SARS-CoV-2 to overcome ISG restriction. TMPRSS2 expression enhanced VSV-SARS-CoV and VSV-SARS-CoV-2 infection at 6 hpi (SI Appendix, Fig. S3A ), compared to control HEK293-hACE2 cells (Fig. 1C ). Un-like IFITM3, CH25H partially retained its antiviral activity and led to reduced VSV-SARS-CoV-2 replication in TMPRSS2-expressing cells (Fig. 3A) . Similarly, wild-type SARS-CoV-2 replication was inhibited by CH25H and 25HC in TMPRSS2-expressing cells (Fig. 3B) .

We next examined the effect of 25HC on SARS-CoV S and SARS-CoV-2 S mediated membrane fusion, since 25HC blocks cell fusion by Nipah F and VSV G proteins (28) , which are class I and class III viral fusion proteins, respectively (35) . We set up an in vitro cell-to-cell fusion assay based on the expression of S, eGFP, ACE2, and TMPRSS2 in HEK293 cells, independent of virus infection (Fig. 3C ). CH25H expression substantially reduced syncytia formation mediated by SARS-CoV-2 S (Fig. 3C) . Although IFITM2 and IFITM3 inhibited VSV-SARS-CoV-2 replication ( Fig. 1 A and B) , neither prevented S-mediated fusion (Fig. 3C) , suggesting a distinct mode of antiviral action. Compared to SARS-CoV-2 S, SARS-CoV S induced weaker cell fusion, as recently reported (36) , and this process was also blocked by CH25H expression (Fig. 3C ). CH25H also inhibited the syncytia formation induced by Western equine encephalitis virus glycoproteins (class II) and VSV-G (class III) but not reovirus FAST p10 (class IV) fusion protein (Fig. 3D ). To mimic the virus-cell membrane fusion, we cotransfected SARS-CoV-2 S and GFP into donor cells and mixed at 1:1 ratio with ACE2 + TMPRSS2 + TdTomato cotransfected target cells. As expected, we observed robust syncytia formation under mock conditions (SI Appendix, Fig. S3B ). CH25H expression in "recipient" cells almost completely abolished cell-cell fusion (SI Appendix, Fig. S3B ). Exogenous 25HC treatment phenocopied CH25H expression and blocked SARS-CoV-2 S-mediated syncytia formation ( Fig. 3E and SI Appendix, Fig. S3B ). Similar to CH25H, 25HC failed to inhibit reovirus FAST p10mediated fusion (SI Appendix, Fig. S3C ).

To define the underlying antiviral mechanisms of the IFN-CH25H-25HC axis further, we investigated whether 25HC acts on viral or host membranes. Preincubation of VSV-SARS-CoV-2 with 10 μM of 25HC for 20 min had no effect on infectivity, as opposed to the pretreatment of host cells (SI Appendix, Fig.  S4A ). The timing of 25HC addition suggests it primarily acted at the entry stage of VSV-SARS-CoV-2 replication (SI Appendix, Fig. S4B ). We examined a series of early events and excluded possible effects of 25HC on: 1) ACE2 surface levels; 2) S cleavage by TMPRSS2; 3) lipid raft localization, stained by a fluorophoreconjugated cholera toxin subunit B; 4) plasma membrane fluidity, stained by 6-dodecanoyl-2-dimethylamino naphthalene (Laurdan) (37); 5) endosomal pH; and 6) its ability to directly bind to recombinant SARS-CoV-2 S protein (SI Appendix, . At 24 hpi, the mRNA level of SARS-CoV-2 N was measured by qRT-PCR and normalized to GAPDH expression. (F) HEK293-hACE2 cells expressing CH25H were transduced with mock or CH25H CRISPR/Cas9 targeting lentiviruses and infected with VSV-SARS-CoV-2 (MOI = 1). At 24 hpi, the mRNA level of VSV N was measured by qRT-PCR and normalized to GAPDH expression. For all panels except A, experiments were repeated at least three times with similar results. The experiment in A was performed twice with average numbers indicated on the graph. Raw data are listed in Dataset S1. Data are represented as mean ± SEM. Statistical significance is from pooled data of the multiple independent experiments (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001). Fig. S4F ), enabling us to use it as a tool to probe the antiviral mechanism of 25HC. Upon host cell uptake, C4 TopFluor-25HC exhibited punctate patterns and partially colocalized with lysobisphosphatidic acid (LBPA)-positive late endosomes and LAMP1 + lysosomes but not Rab4 + recycling endosomes (Fig. 4A) . Thus, we hypothesized that SARS-CoV-2 depends on endosomal trafficking to establish active replication. Consistent with this hypothesis, ectopic expression of Rab5 and Rab7 dominant-negative mutants but not the wild-type proteins significantly decreased VSV-SARS-CoV-2 infection (Fig. 4B and SI Appendix, Fig. S4G ). However, Rab5 and Rab7 mutants did not have an additive effect with 25HC treatment (Fig. 4B) , further suggesting that 25HC may act at these endosomal vesicles.

25HC is capable of binding Niemann-Pick C1 (NPC1) in vitro (39) , which is responsible for the egress of cholesterol from the endosomal/lysosomal compartment (40) . 25HC treatment led to an accumulation of intracellular TopFluorcholesterol (Fig. 4C) . We also observed that in cells stained with filipin, which labels unesterified cholesterol and preferentially recognized cholesterol over 25HC (SI Appendix, Fig.  S5A ), a cholesterol accumulation by 25HC and NPC1 inhibitors itraconazole (ICZ) and U18666A (Fig. 4C) . ICZ treatment significantly reduced VSV-SARS-CoV-2 titers (SI Appendix, Fig. S5B ). The antiviral activity of 25HC and ICZ depended on cholesterol accumulation in the endosomal/lysosomal compartment because the inhibition was markedly diminished in serum-free media that is devoid of cholesterol (SI Appendix, Fig. S5C ). Consistent with our model, pharmacological inhibition of NPC1 by U18666A or genetic depletion of NPC1 by CRISPR/Cas9 potently restricted VSV-SARS-CoV-2 replication (Fig. 4 D and E and SI Appendix, Fig. S5D ). In contrast to chloroquine and camostat, both of which are antiviral but through different mechanisms, 25HC, ICZ, or U18666A efficiently reduced SARS-CoV-2 S-mediated cell-cell fusion (SI Appendix, Fig.  S5E ). Finally, all three compounds suppressed the replication of a recombinant SARS-CoV-2 virus that encodes an mNeon-Green reporter (41) in Vero E6 cells (Fig. 4F) . Collectively, our data support a model that 25HC suppresses SARS-CoV-2 S protein-mediated fusion, which inhibits virus replication, possibly by altering cholesterol levels.

The identification of ISGs against different virus families have provided invaluable insights into both virus entry pathways and host innate immune system evolution (42) (43) (44) (45) . To date, few ISGs have been identified that restrict SARS-CoV replication [IFITMs (33) and GILT (46) ] and SARS-CoV-2 replication [LY6E (20, 21) , IFITMs (21, 22) , and ZAP (47)]. Here, we present evidence that IFN-inducible CH25H and its natural product 25HC restrict S-mediated membrane fusion and block SARS-CoV-2 entry into host cells. 25HC has shown broad antiviral activity against a wide range of enveloped viruses (26, 28, 30, 48) and nonenveloped viruses, such as reovirus (49) and murine norovirus (50) . 25HC treatment did not inhibit the infectivity of rhesus rotavirus RRV strain (Fig. 1D) , in contrast to the inhibition previously seen with the human rotavirus Wa strain (51), possibly because they differ in the endosomal compartment from which they exit into the cytosol (52) . There seem to be two modes of inhibitory mechanisms involved. One requires a high micromolar concentration and more than 6 h of preincubation time to be effective, in the case of reovirus (49) , pseudorabies virus (53) , and human papillomavirus-16 (54) , suggesting an indirect metabolic/cellular pathway-mediated mechanism, whereas the other-which includes influenza A virus (26), Lassa fever virus (55), hepatitis C virus (56) , and SARS-CoV-2 ( Fig. 2 )-functions at a low-micromolar/high-nanomolar range.

Combined with the recent report that apilimod, a PIKfyve kinase inhibitor, effectively inhibits SARS-CoV-2 infection (57), we confirm that this virus reaches late endosomal compartment for membrane fusion and access to the cytosol, at least in ACE2 + TMPRSS2 − cells. Recently, two independent studies also reported the anti-SARS-CoV-2 activity of 25HC (58, 59) . In the second study, Wang et al. (59) observed depletion of cholesterol at the plasma membrane by 25HC treatment, which is consistent with our findings of SARS-CoV-2 S protein-mediated fusion blockade (Fig. 3 C and E) . Taken together, our data suggest a unifying model in which 25HC results in a redistribution of cholesterol and inhibits both endosomal entry and plasma membrane fusion, which potentially explains the CH25H inhibitory activity against wild-type SARS-CoV-2 in both TMPRSS2 − and TMPRSS2 + cells (Fig. 1 C and E and SI Appendix, Fig. S3 A and B) .

One point worth noting is that wild-type VSV is sensitive to 25HC antiviral effect (Fig. 1C) , while its entry is not dependent on NPC1 (60) . Therefore, in the case of SARS-CoV-2, it is plausible that the reduced virus infection in the absence of NPC1 is uncoupled from 25HC antiviral mechanism of action. The latter is likely multifactorial and involves other cholesterol-binding proteins.

Another question that warrants further investigation is whether 25HC interferes with other steps in the SARS-CoV-2 replication cycle. While we observed a relatively weak inhibition of infection at early time points, such as 6 hpi ( Fig. 1C and SI Appendix, Figs. S3A and S4A) , the antiviral effect is magnified by 24 hpi (Figs. 1 D and E, 2C, and 4F ). It will be of interest to examine whether this reflects an antagonism of viral particle maturation or the release or infectivity of virus progeny. Our data instruct potential drug combinations of 25HC in conjunction with those targeting the cytoplasmic steps of the SARS-CoV-2 replication cycle, such as its main protease (61, 62) or polymerase (63) . Further in vivo studies in animal models of SARS-CoV-2 infection and pathogenesis are required to establish the physiological impact of 25HC-based drugs or compounds that modulate antiviral activities.

Plasmids, Cells, Reagents, and Viruses. Plasmids. CH25H, IFIH1, IFITM1, IFITM2, IFITM3, and LY6E were cloned into pLX304 lentiviral vector with a C-terminal V5 tag. Human ACE2 was cloned into pDEST-mCherry vector with an N-terminal mCherry tag. TMPRSS2 and TMPRSS4 plasmids were used as previously described (18) . Single-guide RNA against CH25H or NPC1 (SI Appendix, Table S1 ) was cloned into lenti-CRISPR_v2 vector (Addgene, #52961). CH25H point mutations were introduced by QuikChange II site-directed mutagenesis (Agilent, #200524) using primers in SI Appendix, Table S1 . GFP-tagged Rab5 and Rab7 constructs were used as reported previously (64) . Codon-optimized SARS-CoV-2 S was a kind gift from Nevan Krogan at the University of California, San Francisco, CA (65) . pCAGGS-SARS-CoV S was a kind gift of Paul Bates at the University of Pennsylvania, Philadelphia, PA (66) . pMIG-WEEV-IRES-GFP plasmid was generated by Zhuoming Liu in the S.P.J.W. laboratory at the Washington University School of Medicine in St. Louis, St. Louis, MO. PM-GFP and VSV-G plasmids were obtained from Addgene (#21213 and #12259, respectively). pCAGGS-FAST-p10 from pteropine orthoreovirus was generated in the Kobayashi laboratory at the Osaka University, Japan (67) . pEGFP-N1 and pCMV-TdTomato were obtained from Clontech. Cells. Human embryonic kidney cell line HEK293 (CRL-1573) were originally obtained from American Type Culture Collection (ATCC) and cultured in complete DMEM. Rhesus kidney epithelial cell lines MA104 cells were cultured in complete M199 medium. HEK293T, Vero cells (CCL81, ATCC), and Vero E6 cells (CRL-1586, ATCC) were cultured in complete DMEM (Corning). HEK293-hACE2-mCherry cells were cultured in complete DMEM with G418 addition (500 μg/mL). HEK293-hACE2 cells and HEK293 cells stably expressing ACE2 and TMPRSS2 were used as previously described (18) . For overexpression, HEK293-hACE2 cells were transduced with lentiviruses encoding CH25H for 2 d in the presence of polybrene (8 μg/mL) and cultured in DMEM containing 5 μg/mL of blasticidin. For CRISPR knockout, HEK293-hACE2-TMPRSS2 cells were transduced with lentiviruses encoding Cas9 and singleguide RNA against CH25H or NPC1 for 2 d and cultured in the presence of puromycin (1 μg/mL). Reagents. 25HC, 7-α, 25-diHC, trypsin, U18666A, and filipin were purchased from Sigma-Aldrich. C4 TopFluor-25HC and TopFluor-cholesterol were purchased from Avanti Polar Lipids. The 6-Dodecanoyl-2-dimethylaminonaphthalene (Laurdan, D250), cholera toxin subunit B (C34777), and pHrodo AM Variety Pack (P35380) were purchased from Thermo Fisher. ICZ and camostat were purchased from Selleck Chemicals. Chloroquine (tlrl-chq) was purchased from Invivogen. The viability of MA104 cells after drug treatment was determined using the Cell Counting Kit 8 (ab228554, Abcam). Viruses. Recombinant VSV-eGFP-SARS-CoV-2 was previously described (14) . VSV-eGFP-SARS-CoV was constructed in a similar manner. Adenovirus (serotype 5) and rotavirus (rhesus RRV strain) were propagated and used as previously described (68) . A clinical isolate of SARS-CoV-2 (2019-nCoV/USA-WA1/2020 strain) was obtained from Natalie Thornburg at the Centers for Disease Control and Prevention, Atlanta, GA. An mNeonGreen SARS-CoV-2 reporter virus was used as previously reported (41) . SARS-CoV-2 viruses were passaged in Vero CCL81 cells and titrated by focus-forming assay on Vero E6 cells. Plaque assays were performed in MA104 cells seeded in six-well plates using an adapted version of the rotavirus plaque assay protocol (69) . The plaque plates were scanned by Amersham Typhoon 5 (GE) and diameters were measured by ImageJ (NIH).

Identification and Quantification of Oxysterols. Oxysterols were extracted from pellets (3 × To extract secreted oxysterols from the culture medium, medium (1 mL) was added drop-wise, with sonication in an ultrasonic bath (5 min), to 2.3 mL of absolute ethanol containing the same amount of internal standards, as above, to give a solution of 3.3 mL of 70% ethanol. The oxysterols were then separated from cholesterol, derivatized with Girard P reagent and analyzed by LC-MS(MS n ) on a Orbitrap Elite, as described previously (70) . Identification was performed by comparing retention time, exact mass, and MS n spectra to authentic standards and quantification was performed by stable isotope dilution using reconstructed ion-chromatograms generated in the Orbitrap.

Cardiomyocyte Infection. Human induced pluripotent stem cell-derived cardiomyocytes (R1117) were purchased from Cellular Dynamics International and seeded onto a 24-well plate coated with 0.1% gelatin (07903, Stemcell Technologies) at 1.36 × 10 5 cells per well, following manufacturer's recommendations. The cells were seeded in culture (37°C, 5% CO 2 ) for 48 h in plating medium and then changed to maintenance media, which was replaced every 2 d. VSV-SARS-CoV-2 infections were performed at day 6 after cell seeding.

SARS-CoV-2-Lenti-GFP Pseudovirus Preparation. Confluent HEK293T cells in sixwell plates were cotransfected with plasmids pLenti-CMV-GFP-Puro (Addgene #17448) (71), psPAX2 (Addgene #12260), and pcDNA3.1-SARS-CoV-2spike (Addgene #145032) (72) with a mass ratio of 4:3:1 (1.6 μg, 1.2 μg, and 0.4 μg, respectively) by Lipofectamine 3000 (Life Technologies). The supernatant was collected at days 2, 3, and 4 posttransfection and combined. To concentrate the pseudovirus particles from the collected supernatant, polyethylene glycol (PEG)-8000 powder was added to a final concentration (wt/vol) of 10% and the mixture was gently rotated at 4°C overnight, followed by centrifugation at 1,000 × g for 30 min at 4°C. The pellet was dissolved in serum-free DMEM/F12 medium with 1% volume of the original supernatant samples. The concentrated virus stock was aliquoted and stored at −80°C. For HIV-1 p24 titration assay, the concentrated pseudovirus particles were diluted in PBS (or DMEM/F12 medium) by 10,000-fold and subjected to the titration assay by using HIV-1 p24 quantitation ELISA Kit (Abcam) according to the manufacturer's directions.

RNA Extraction and Quantitative PCR. Total RNA was extracted from cells using RNeasy Mini kit (Qiagen) and reverse transcription was performed with High Capacity RT kit and random hexamers, as previously described (73) . Quantitative PCR was performed using the AriaMX (Agilent) with a 25-μL reaction, composed of 50 ng of cDNA, 12.5 μL of Power SYBR Green master mix or Taqman master mix (Applied Biosystems), and 200 nM both forward and reverse primers. All SYBR Green primers and Taqman probes used in this study are listed in SI Appendix, Table S1 .

Flow Cytometry. HEK293-hACE2 or HEK293-hACE2-TMPRSS2 cells with or without CH25H expression were inoculated with wild-type VSV-GFP, VSV-SARS-CoV, or VSV-SARS-CoV-2 at a multiplicity of infection (MOI) = 10 (based on titers in Vero cells) for 1 h at 37°C. At 6 hpi, cells were harvested and fixed in 4% PFA. GFP + cells were determined by BD LSRFortessa X-20 cell analyzer and analyzed by FlowJo v10.6.2 (BD).

Brightfield and Immunofluorescence Microscopy. For brightfield and epifluorescence, cultured cells were imaged by REVOLVE4 microscope (ECHO) with a 10× objective. For confocal microscopy, samples in eight-well chamber slides were fixed in 4% paraformaldehyde for 10 min at room temperature and stained as previously described (74) . Cells were permeabilized and stained with antibodies against DAPI (P36962, Thermo Fisher), LAMP1 (9091S, Cell Signaling), LBPA (MABT837, Sigma), and Rab4 (ab13252, Abcam) at room temperature for 1 h. For filipin staining, cells were fixed and incubated with 50 μg/mL filipin (SAE0087, Sigma-Aldrich) at 37°C for 30 min. Stained cells were washed with PBS, whole-mounted with Antifade Mountant, and imaged with a Zeiss LSM880 Confocal Microscope at the Molecular Microbiology imaging core facility at Washington University in St. Louis. Images were visualized by Volocity v6.3 and quantification was determined by ImageJ (NIH).

Western Blotting. Cell lysates were harvest in RIPA buffer supplemented with protease inhibitor mixture and phosphatase inhibitor. Proteins were resolved in SDS/PAGE and analyzed by antibody as described previously (75) using the following antibodies and dilutions: ACE2 (MAB933, R&D Systems), GAPDH (631402, BioLegend), GFP (2555S, Cell Signaling), NPC1 (ab124801, Abcam), SARS-CoV-2 S1 (40590-T62, Sino Biological), SARS-CoV-2 S2 (40592-T62, Sino Biological), and V5 (13202S, Cell Signaling). Secondary antibodies were antirabbit (7074, Cell Signaling) or anti-mouse (7076, Cell Signaling) IgG horseradish peroxidase-linked antibodies. Protein bands were visualized with Clarity ECL substrate and a Bio-Rad Gel Doc XR system. Statistical Analysis. All bar graphs were displayed as means ± SEM. Statistical significance in the data in Figs. 1 E and F, 2C, 3B, and 4E and SI Appendix, Figs. S1 C and D, S2B, and S5B was calculated by Student's t test using Prism 8.4.2 (GraphPad). Statistical significance in the data in Figs. 1 B and D, 2 D, F-H, 3 C-E, and 4 A and B and SI Appendix, Figs. S1G, S2E, S3 B and C, S4A, and S5E was calculated by pairwise ANOVA using Prism 8. Nonlinear regression (curve fit) was performed to calculate EC 50 and CC 50 values for Figs. 2B and 4 D and F and SI Appendix, Fig. S4E . All data are presented as *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001. All experiments other than Fig. 1A were repeated at least three times. Fig. 1A was performed twice with average numbers indicated on the graph. The raw data are included in Dataset S1.

Data Availability. All study data are included in the article and supporting information.

A new coronavirus associated with human respiratory disease in China

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Interferon-lambda: A new addition to an old family

Type I IFN modulates innate and specific antiviral immunity

Interferon-stimulated genes and their antiviral effector functions

Imbalanced hostresponse to SARS-CoV-2 drives development of COVID-19

SARS-CoV-2 productively infects human gut enterocytes

SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology

SARS-CoV-2 is sensitive to type I interferon pretreatment

Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells

Vanderheiden et al, Type I and type III IFN restrict SARS-CoV-2 infection of human airway epithelial cultures

Side effects of alpha interferon in chronic hepatitis C

Type I and III interferons disrupt lung epithelial repair during recovery from viral infection

Neutralizing antibody and soluble ACE2 inhibition of a replicationcompetent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Immune signaling by RIG-I-like receptors

LY6E impairs coronavirus fusion and confers immune control of viral disease

LY6E restricts entry of human coronaviruses, including currently pandemic SARS-CoV-2

Opposing activities of IFITM proteins in SARS-CoV-2 infection

cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism

Oxysterols direct immune cell migration via EBI2

Interferon-stimulated genes: What do they all do?

The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response

Cholesterol 25-hydroxylase negatively regulates porcine intestinal coronavirus replication by the production of 25-hydroxycholesterol

Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol

Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection

Interferon-inducible cholesterol-25-hydroxylase inhibits hepatitis C virus replication via distinct mechanisms

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

TMPRSS2 activates the human coronavirus 229E for cathepsinindependent host cell entry and is expressed in viral target cells in the respiratory epithelium

Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus

HCA Lung Biological Network, SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes

Virus and cell fusion mechanisms

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

IFITM proteins restrict viral membrane hemifusion

A lipid-based partitioning mechanism for selective incorporation of proteins into membranes of HIV particles

Structure of N-terminal domain of NPC1 reveals distinct subdomains for binding and transfer of cholesterol

Niemann-pick C1 disease gene: Homology to mediators of cholesterol homeostasis

An infectious cDNA clone of SARS-CoV-2

A CRISPR screen identifies IFI6 as an ER-resident interferon effector that blocks flavivirus replication

Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity

A diverse range of gene products are effectors of the type I interferon antiviral response

Restriction of HIV-1 and other retroviruses by TRIM5

GILT restricts the cellular entry mediated by the envelope glycoproteins of SARS-CoV, Ebola virus and Lassa fever virus

The zinc finger antiviral protein restricts SARS-CoV-2

Interferon-inducible cholesterol-25-hydroxylase restricts hepatitis C virus replication through blockage of membranous web formation

25-Hydroxycholesterol production by the cholesterol-25-hydroxylase interferon-stimulated gene restricts mammalian reovirus infection

The oxysterol 25-hydroxycholesterol inhibits replication of murine norovirus

25-Hydroxycholesterol and 27-hydroxycholesterol inhibit human rotavirus infection by sequestering viral particles into late endosomes

Rotavirus entry: A deep journey into the cell with several exits

Cholesterol 25-hydroxylase acts as a host restriction factor on pseudorabies virus replication

Inhibition of pathogenic non-enveloped viruses by 25-hydroxycholesterol and 27-hydroxycholesterol

25-Hydroxycholesterol inhibition of Lassa virus infection through aberrant GP1 glycosylation

Identification of cholesterol 25-hydroxylase as a novel host restriction factor and a part of the primary innate immune responses against hepatitis C virus infection

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2

25-Hydroxycholesterol is a potent SARS-CoV-2 inhibitor

Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol

Ebola virus entry requires the cholesterol transporter Niemann-Pick C1

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Structure of the RNA-dependent RNA polymerase from COVID-19 virus

Rhesus rotavirus trafficking during entry into MA104 cells is restricted to the early endosome compartment

A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing

Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry

Entirely plasmid-based reverse genetics system for rotaviruses

Drebrin restricts rotavirus entry by inhibiting dynamin-mediated endocytosis

Rotavirus VP3 targets MAVS for degradation to inhibit type III interferon expression in intestinal epithelial cells

Quantitative charge-tags for sterol and oxysterol analysis

A versatile viral system for expression and depletion of proteins in mammalian cells

Structural basis of receptor recognition by SARS-CoV-2

Dynamic expression profiling of type I and type III Interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression

STAG2 deficiency induces interferon responses via cGAS-STING pathway and restricts virus infection

Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth

ACKNOWLEDGMENTS. We thank Drs. Rohit Pappu (School of Engineering), Anil Cashikar, Steven Paul (Department of Psychiatry), and David Holtzman